Search research articles
Contact Us
Filters
Showing results (51-60 of 79) with videos related to
Page
of 8
Sort By:
European Urology Focus
|
June 5, 2024
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma
Cora N Sternberg, Yohann Loriot, Ernest Choy, et al.
Clinical Genitourinary Cancer
|
April 14, 2024
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study
Veronica Mollica, Francesco Massari, Marco Maruzzo, et al.
JCO Global Oncology
|
July 8, 2025
Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study
Mimma Rizzo, Andrey Soares, Shilpa Gupta, et al.
Targeted Oncology
|
August 6, 2024
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project
Alessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, et al.
Tumori
|
June 8, 2022
Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®)
Caterina Caminiti, Jane Bryce, Silvia Riva, et al.
Clinical and Experimental Medicine
|
November 2, 2023
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study
Matteo Santoni, Francesco Massari, Hideki Takeshita, et al.
Frontiers in Immunology
|
March 12, 2026
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, et al.
Targeted Oncology
|
May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
JCO Precision Oncology
|
September 14, 2020
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis
Anuradha Jayaram, Anna Wingate, Daniel Wetterskog, et al.
Biology Direct
|
June 23, 2025
Multimodal deep learning for predicting neoadjuvant treatment outcomes in breast cancer: a systematic review
Eriseld Krasniqi, Lorena Filomeno, Teresa Arcuri, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 79) with videos related to
Sort By:
Page
of 8
European Urology Focus
|
June 5, 2024
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma
Cora N Sternberg, Yohann Loriot, Ernest Choy, et al.
Clinical Genitourinary Cancer
|
April 14, 2024
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study
Veronica Mollica, Francesco Massari, Marco Maruzzo, et al.
JCO Global Oncology
|
July 8, 2025
Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study
Mimma Rizzo, Andrey Soares, Shilpa Gupta, et al.
Targeted Oncology
|
August 6, 2024
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project
Alessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, et al.
Tumori
|
June 8, 2022
Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®)
Caterina Caminiti, Jane Bryce, Silvia Riva, et al.
Clinical and Experimental Medicine
|
November 2, 2023
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study
Matteo Santoni, Francesco Massari, Hideki Takeshita, et al.
Frontiers in Immunology
|
March 12, 2026
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, et al.
Targeted Oncology
|
May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
JCO Precision Oncology
|
September 14, 2020
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis
Anuradha Jayaram, Anna Wingate, Daniel Wetterskog, et al.
Biology Direct
|
June 23, 2025
Multimodal deep learning for predicting neoadjuvant treatment outcomes in breast cancer: a systematic review
Eriseld Krasniqi, Lorena Filomeno, Teresa Arcuri, et al.
Page
of 8